» interventional cardiology | drug-eluting stent

Adjust Font Size:

The MiStent^® DES is an investigational drug-eluting stent in the clinical stage of development that has been designed to optimize healing. Read more. Euro - PCR Meeting, May 18th 2011 Presentation: MiStent^TM DES: A novel third generation DES with a fully-absorbable coating and enhanced drug delivery capabilities.		November 8, 2011 — Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System Read more. November 2, 2011 — Micell Technologies Announces Presentation of Clinical Data at TCT 2011 Read more.		Micell Technologies is bringing together the clinical advantages of a drug-eluting stent with the long-term safety and stability of a bare metal stent. The resulting drug-delivery device is intended to redefine the field of interventional cardiology. Read more.


Caution: The Micell products described on this website are investigational devices that are not available for sale in any country. Home \| About Us \| Therapeutic Focus \| Product Pipeline \| Technology \| News \| Terms of Use \| Privacy Policy \| Site Map		© 2012 Micell Technologies, Inc. All rights reserved. "Micell" and "MiStent" are registered trademarks of Micell Technologies, Inc.